Abliva AB Revenue and Competitors
Estimated Revenue & Valuation
- Abliva AB's estimated annual revenue is currently $3.4M per year.
- Abliva AB's estimated revenue per employee is $201,000
Employee Data
- Abliva AB has 17 Employees.
- Abliva AB grew their employee count by -6% last year.
Abliva AB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
Abliva AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Abliva AB?
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⺠regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
keywords:N/A
N/A
Total Funding
17
Number of Employees
$3.4M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Abliva AB News
The shareholders in Isofol Medical AB (publ), Reg. No. ... of Lidds AB and Glactone Pharma AB, a board member of Abliva AB and Innotext AB,...
... is six tracks with special appearances by Ab-Liva, Pharrell, Kash Doll and Clipse. Pusha T made another double EP release last month,...
Other Companies in Lund
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.3M | 17 | -6% | N/A |
#2 | $1.4M | 17 | 0% | N/A |
#3 | $1.4M | 17 | -23% | N/A |
#4 | $1.7M | 19 | -5% | N/A |
#5 | $3.1M | 20 | 11% | N/A |